Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune, Inc.'s Chief Business Officer, Jordt Raymond M, increased his direct ownership through the company’s employee stock purchase plan. On January 31, 2026, he acquired 4,571 shares of common stock at a price of $3.07 per share under the 2019 Employee Stock Purchase Plan, tied to the purchase period from August 1, 2025 through January 31, 2026. Following this automatic plan-based purchase, he directly holds 70,107 shares of Altimmune common stock.
Altimmune Inc received an updated Schedule 13G/A from The Vanguard Group, which reports beneficial ownership of 9,491,159 shares of Altimmune common stock, representing 9.09% of the outstanding class.
Vanguard reports no sole voting or dispositive power, with shared voting power over 744,210 shares and shared dispositive power over all 9,491,159 shares. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report holdings separately. Vanguard states the shares are held in the ordinary course of business, not to change or influence control, and that its clients have the economic rights to dividends and sale proceeds, with no single client owning more than 5%.
Altimmune, Inc.’s Chief Business Officer, Raymond M. Jordt, reported routine equity compensation activity. On January 27, 2026, 15,850 Restricted Stock Units (RSUs) were converted into an equal number of common shares at $0 per share. A separate transaction shows 4,229 common shares were surrendered at $6.18 per share to Altimmune solely to cover taxes associated with the RSU vesting. Following these transactions, Jordt directly owns 65,536 shares of common stock and 47,550 RSUs, which each represent a contingent right to receive one common share. The RSUs vest in substantially equal annual installments over four years following January 27, 2025, subject to continued service, and have no expiration date.
Altimmune, Inc. director Vipin K. Garg reported RSU vesting and related share movements. On January 27, 2026, 41,200 Restricted Stock Units converted into the same number of Altimmune common shares at a stated price of $0 per share.
To cover taxes on the RSU vesting, 17,898 common shares were surrendered to the issuer at a price of $6.18 per share. After these transactions, Garg directly held 402,450 Altimmune common shares and 123,600 RSUs, which vest in substantially equal annual installments over four years following January 27, 2025.
Altimmune Chief Scientific Officer Scot Roberts reported equity compensation activity involving company stock. On January 27, 2026, he converted 15,850 Restricted Stock Units into an equal number of Altimmune common shares at $0 per share, reflecting standard RSU settlement. In a related tax withholding step, 4,748 shares were surrendered to Altimmune at $6.18 per share to cover taxes due on the vesting. Following these transactions, Roberts directly owned 95,395 shares of common stock and 47,550 RSUs, which each represent a right to receive one share of common stock as they vest over time.
Altimmune, Inc. entered into a securities purchase agreement with a new institutional investor for a registered direct offering of common stock and pre-funded warrants expected to raise approximately $75 million in gross proceeds.
The investor will purchase 12,397,920 shares of common stock and pre-funded warrants to buy up to 4,647,534 additional shares at a nominal $0.001 exercise price per warrant. The pre-funded warrants are immediately exercisable, do not expire, and are subject to a beneficial ownership cap starting at 9.99%, which can be increased up to 19.99% with notice. Directors and executive officers agreed to 30-day lock-up restrictions after closing.
Altimmune, Inc. is conducting a registered direct offering of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 additional shares, for a total offering price of $75,000,000. The company expects net proceeds of about $70.4 million after fees and expenses.
Altimmune plans to use the cash, together with existing resources, to advance clinical development and manufacturing for its lead drug pemvidutide, including preparation for a Phase 3 trial in MASH and potential commercial launch, and for general corporate purposes. Management currently expects available funds to support operations through the end of 2027, subject to development plans.
Altimmune, Inc. Chief Business Officer Raymond M. Jordt reported an RSU vesting and related tax withholding transaction. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at an exercise price of $0.
On the same date, 3,855 common shares were surrendered to Altimmune at $5.5 per share to cover taxes due on the RSU vesting. After these transactions, Jordt directly held 53,915 shares of common stock and 29,200 RSUs. The RSUs vest in substantially equal annual installments over four years following January 25, 2024, contingent on continued service.
Altimmune director Vipin K. Garg reported an RSU vesting and related tax share surrender. On January 25, 2026, 42,050 Restricted Stock Units were converted into 42,050 shares of common stock at a stated price of $0 per share. On the same date, 17,984 shares of common stock were surrendered to Altimmune at $5.50 per share to cover taxes due on the RSU vesting. After these transactions, Garg directly holds 379,148 shares of Altimmune common stock and 84,100 RSUs, which vest in substantially equal annual installments over four years starting January 25, 2024.
Altimmune, Inc. Chief Scientific Officer Roberts M. Scot reported routine equity compensation activity. On January 25, 2026, 14,600 Restricted Stock Units were converted into an equal number of Altimmune common shares at a price of $0 per share, reflecting RSU vesting. On the same date, 4,373 common shares were surrendered to the company at $5.50 per share to cover taxes associated with the RSU vesting, rather than being sold on the open market. After these transactions, Scot directly beneficially owned 84,293 shares of common stock and 29,200 RSUs, which continue to vest in substantially equal annual installments over four years following January 25, 2024, conditioned on continued service.